FulgentExome | Fulgent Genetics

Female scientist with pipet looking at sample tube.

NEW PRODUCT

FulgentExome is CE-Marked for Quality and Compliance

FulgentExome provides a robust, CE-marked solution for clinical exome analysis, enabling the identification of germline variants associated with genetic disorders. Powered by advanced NGS technology and a proprietary CE-marked bioinformatics pipeline (FPLM), FulgentExome ensures high accuracy, reliability, and expert-driven interpretation to support clinical diagnostics.

Features

Comprehensive Coverage
Targets 6,717 clinically significant genes, providing >99% coverage at 20x depth for coding regions and splice sites.
CE-IVD Compliance
Certified under IVDR 2017/746, ensuring quality and compliance for clinical use in the EU.
Phenotype-Driven
Genetic results are interpreted in the context of the patient's disease for maximum clinical relevance and actionability.

Request Sample Report

In-Depth Analysis

FulgentExome provides in-depth insights into the genetic basis of disease by detecting single nucleotide variants (SNVs), small insertions and deletions (INDELs), and copy number variants (CNVs) across the exome.

Our test leverages a phenotype-driven approach, tailoring analysis to the patient's clinical presentation and family history. Findings are interpreted using established professional guidelines — providing clinicians with clear, patient-centric results to guide diagnosis and care.

Important

Results must be interpreted by qualified healthcare professionals in conjunction with clinical findings, family history, and other relevant diagnostic information.

TARGET USERS

Clinical laboratory professionals
Medical geneticists
Healthcare providers
Genetic counselors

CLINICAL APPLICATIONS

Hereditary disease diagnosis
Genetic variant identification
Clinical decision support
Cascade testing programs

Liquid handler with multiple pipet tips.

Product Highlights

Advanced Technology

Employs hybrid capture and sequencing on Illumina NovaSeq platforms, delivering high sensitivity and specificity for detecting single nucleotide variants (SNVs), insertions/deletions (INDELs), and copy number variants (CNVs).

Extensive Gene Coverage

Covers 6,717 protein-coding genes with established links to genetic disorders relevant to numerous specialties including pediatrics, oncology, and neurology.

Phenotype-Centric Approach

Customizable analysis through a phenotype-centric approach to improve targeting of clinical indications for greater precision and impact.

TEST DETAILS

FulgentExome is a qualitative, semi-automated, next-generation sequencing (NGS) based system designed for clinical exome analysis to identify germline variants for the purpose of aiding the diagnosis of suspected genetic condition(s) within a patient's clinical and family history.

Sensitivity: ≥99% for SNVs and INDELs
Turnaround Time: 3-5 weeks

SPECIMEN TYPES ACCEPTED

Peripheral Blood
Buccal or Saliva Swabs
Cultured Cells
Extracted DNA

QUALITY STANDARDS

Manufactured in an ISO 13485-compliant facility and adheres to ISO 15189 for laboratory testing services.

FULGENTEXOME REPORTS

The FulgentExome report is thoughtfully designed with a clean, organized layout, making complex genetic information easier to read, interpret, and apply in clinical practice.

Regulatory Status: CE-marked in vitro diagnostic device under IVDR

How to Order

Contact Our Team

Reach out to learn more about FulgentExome's capabilities at info@fulgentgenetics.com

Onboard Your Facility

Set up your account and let us guide you through your first order.

Order & Submit Samples

Send patient specimens to our laboratory for processing. Reports are sent to the ordering provider within 3-5 weeks.

REGULATORY DISCLAIMERS

CE-Marking: FulgentExome is CE-IVD certified under IVDR (EU) 2017/746, ensuring compliance with European regulatory requirements.
Intended Use: For clinical diagnostics performed by qualified healthcare professionals.
Quality Management: Operates under ISO 13485-compliant manufacturing and ISO 15189 laboratory standards.

REGULATORY INFORMATION (Based on EU IVDR 2017/746)

This test will be conducted using CE-marked devices that comply with Regulation (EU) 2017/746 on in vitro diagnostic medical devices. The devices involved—FulgentExome and FulgentPLM—have defined intended uses and comprehensive documentation, including warnings and precautions, operating instructions, and information regarding biological and hazardous substance content, as outlined in their respective Instructions for Use (IFUs). These IFUs are available internally to trained Fulgent personnel, who are the intended users of the FulgentExome and FulgentPLM assays. Clinicians - and their patients - who request these tests may access the IFUs and SSPs of these CE-marked devices by contacting the following email address: info@fulgentgenetics.com.